SG11201500922RA - Methods and kits for screening patients with a cancer - Google Patents
Methods and kits for screening patients with a cancerInfo
- Publication number
- SG11201500922RA SG11201500922RA SG11201500922RA SG11201500922RA SG11201500922RA SG 11201500922R A SG11201500922R A SG 11201500922RA SG 11201500922R A SG11201500922R A SG 11201500922RA SG 11201500922R A SG11201500922R A SG 11201500922RA SG 11201500922R A SG11201500922R A SG 11201500922RA
- Authority
- SG
- Singapore
- Prior art keywords
- kits
- cancer
- methods
- screening patients
- screening
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000012216 screening Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305975 | 2012-08-06 | ||
| PCT/EP2013/066425 WO2014023706A1 (en) | 2012-08-06 | 2013-08-05 | Methods and kits for screening patients with a cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201500922RA true SG11201500922RA (en) | 2015-04-29 |
Family
ID=46762994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201500922RA SG11201500922RA (en) | 2012-08-06 | 2013-08-05 | Methods and kits for screening patients with a cancer |
Country Status (13)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY188826A (en) | 2008-12-09 | 2022-01-06 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CN107148274A (zh) * | 2014-08-19 | 2017-09-08 | 国立大学法人冈山大学 | 增强免疫细胞功能的方法和评估免疫细胞多功能性的方法 |
| WO2016109546A2 (en) | 2014-12-30 | 2016-07-07 | Genentech, Inc. | Methods and compositions for prognosis and treatment of cancers |
| SG11201809317VA (en) * | 2016-05-09 | 2018-11-29 | Inst Nat Sante Rech Med | Methods for classifying patients with a solid cancer |
| AU2018228873A1 (en) | 2017-03-01 | 2019-08-29 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| US11311945B2 (en) | 2018-03-22 | 2022-04-26 | Sumitomo Electric Hardmetal Corp. | Surface-coated cutting tool and method for manufacturing same |
| WO2020072223A1 (en) * | 2018-10-01 | 2020-04-09 | Nantomics, Llc | Evidence based selection of patients for clinical trials using histopathology |
| WO2020245155A1 (en) | 2019-06-03 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for modulating a treatment regimen |
| AU2020378280A1 (en) | 2019-11-07 | 2022-04-07 | Feng Biosciences, Ltd. | Classification of tumor microenvironments |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| EP4172621A1 (en) | 2020-06-30 | 2023-05-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies |
| WO2022002874A1 (en) | 2020-06-30 | 2022-01-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery |
| WO2023175366A1 (en) | 2022-03-17 | 2023-09-21 | Veracyte | Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4888278A (en) | 1985-10-22 | 1989-12-19 | University Of Massachusetts Medical Center | In-situ hybridization to detect nucleic acid sequences in morphologically intact cells |
| US5447841A (en) | 1986-01-16 | 1995-09-05 | The Regents Of The Univ. Of California | Methods for chromosome-specific staining |
| US6280929B1 (en) | 1986-01-16 | 2001-08-28 | The Regents Of The University Of California | Method of detecting genetic translocations identified with chromosomal abnormalities |
| US5427932A (en) | 1991-04-09 | 1995-06-27 | Reagents Of The University Of California | Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using |
| US5472842A (en) | 1993-10-06 | 1995-12-05 | The Regents Of The University Of California | Detection of amplified or deleted chromosomal regions |
| US6942970B2 (en) | 2000-09-14 | 2005-09-13 | Zymed Laboratories, Inc. | Identifying subjects suitable for topoisomerase II inhibitor treatment |
| JP2002363169A (ja) * | 2001-06-08 | 2002-12-18 | Fujiyakuhin Co Ltd | 抗腫瘍活性を有する複素環化合物 |
| US20110152115A1 (en) * | 2003-09-03 | 2011-06-23 | The United States of America, as represented by the Secretary, Department of Health and | Methods for identifying, diagnosing, and predicting survival of lymphomas |
| EP1664762A4 (en) * | 2003-09-03 | 2008-08-13 | Us Gov Health & Human Serv | METHOD OF IDENTIFYING AND DIAGNOSIS OF, AND VIEWING, SURVIVAL IN LYMPHOMA |
| EP1893241A2 (en) | 2005-04-28 | 2008-03-05 | Ventana Medical Systems, Inc. | Fluorescent nanoparticles conjugated to antibodies via a peg linker |
| CA2609702C (en) | 2005-04-28 | 2013-05-28 | Ventana Medical Systems, Inc. | Antibody conjugates via heterobifunctional peg linkers |
| EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| ES2677555T3 (es) | 2005-11-23 | 2018-08-03 | Ventana Medical Systems, Inc. | Conjugado molecular |
| US20110070582A1 (en) * | 2008-11-03 | 2011-03-24 | Source Precision Medicine, Inc. d/b/d Source MDX | Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects |
| HUE051674T2 (hu) * | 2010-09-24 | 2021-03-29 | Niels Grabe | Eszközök és eljárások rákos beteg kezelésére adott válaszának elõrejelzésére |
| WO2012095448A1 (en) * | 2011-01-11 | 2012-07-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the outcome of a cancer in a patient by analysing gene expression |
-
2013
- 2013-08-05 EP EP13745117.5A patent/EP2880180B1/en active Active
- 2013-08-05 SG SG11201500922RA patent/SG11201500922RA/en unknown
- 2013-08-05 PT PT13745117T patent/PT2880180T/pt unknown
- 2013-08-05 TR TR2018/19211T patent/TR201819211T4/tr unknown
- 2013-08-05 WO PCT/EP2013/066425 patent/WO2014023706A1/en active Application Filing
- 2013-08-05 ES ES13745117T patent/ES2702722T3/es active Active
- 2013-08-05 EP EP18196198.8A patent/EP3470531A1/en not_active Withdrawn
- 2013-08-05 DK DK13745117.5T patent/DK2880180T3/en active
- 2013-08-05 AU AU2013301609A patent/AU2013301609B2/en active Active
- 2013-08-05 JP JP2015525857A patent/JP6559566B2/ja active Active
- 2013-08-05 US US14/420,053 patent/US20150218650A1/en not_active Abandoned
- 2013-08-05 PL PL13745117T patent/PL2880180T3/pl unknown
- 2013-08-05 LT LTEP13745117.5T patent/LT2880180T/lt unknown
- 2013-08-05 CA CA2881389A patent/CA2881389C/en active Active
-
2019
- 2019-07-17 JP JP2019131862A patent/JP6995091B2/ja active Active
-
2020
- 2020-06-09 US US16/896,736 patent/US20200299784A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| LT2880180T (lt) | 2019-01-25 |
| CA2881389A1 (en) | 2014-02-13 |
| JP6559566B2 (ja) | 2019-08-14 |
| US20150218650A1 (en) | 2015-08-06 |
| EP2880180A1 (en) | 2015-06-10 |
| PL2880180T3 (pl) | 2019-04-30 |
| WO2014023706A1 (en) | 2014-02-13 |
| TR201819211T4 (tr) | 2019-01-21 |
| AU2013301609B2 (en) | 2019-03-14 |
| JP2019176880A (ja) | 2019-10-17 |
| JP2015530877A (ja) | 2015-10-29 |
| DK2880180T3 (en) | 2019-01-14 |
| JP6995091B2 (ja) | 2022-01-14 |
| PT2880180T (pt) | 2018-12-27 |
| AU2013301609A1 (en) | 2015-02-26 |
| CA2881389C (en) | 2022-01-04 |
| EP2880180B1 (en) | 2018-10-03 |
| ES2702722T3 (es) | 2019-03-05 |
| EP3470531A1 (en) | 2019-04-17 |
| US20200299784A1 (en) | 2020-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201500922RA (en) | Methods and kits for screening patients with a cancer | |
| EP2776832A4 (en) | BIOMARKER FOR BUBBLE CANCER AND METHOD FOR ITS USE | |
| IL239262A0 (en) | Scanning methods | |
| IL235826A0 (en) | Diazaspirocycloalkane and azaspirocycloalkane | |
| IL235512A0 (en) | New methods | |
| EP2847593A4 (en) | METHODS FOR PREDICTING AND DETECTING THE RISK OF CANCER | |
| EP2685807A4 (en) | SCREENING METHODS | |
| EP2841603A4 (en) | METHODS OF ASSESSING THE STATUS OF LUNG CANCER | |
| IL237436A0 (en) | A method for screening cancer | |
| EP2908116A4 (en) | SCREENING DEVICE AND SCREENING METHOD | |
| EP2880423A4 (en) | NANOCAPTOR FOR SPECTROSCOPY DIFFUSION | |
| EP2924691A4 (en) | SCINTILLATE PANEL AND METHOD FOR PRODUCING A SCINTILLATE PANEL | |
| IL236436A0 (en) | Kits and methods for the detection of cyanide | |
| SI2758532T1 (sl) | Presejalni postopki in njihove uporabe | |
| GB201216289D0 (en) | A screening procedure | |
| HUE046533T2 (hu) | Eszközök és eljárások metán elõállítására | |
| IL234080A (en) | Tetrazolylhydroxyimino derivatives and methods for their production | |
| SG11201501838RA (en) | Completion assembly and methods for use thereof | |
| GB201213770D0 (en) | Screening methods | |
| EP2721410A4 (en) | BIOMARKERS FOR THE DIAGNOSIS AND TREATMENT OF EPITHELIAL CANCER | |
| GB201221092D0 (en) | Assemblies and methods | |
| GB201202870D0 (en) | Screening methods | |
| GB201202945D0 (en) | Novel cancer therapies and methods | |
| GB201212964D0 (en) | Diagnostic and prognostic methods | |
| GB201108085D0 (en) | Novel cancer therapies and methods |